Pharmaceuticals, Biotechnology and Life Sciences
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new AUSTEDO® (deutetrabenazine) data will be presented at the 32nd annual Psych Congress, October 3-6, 2019 in San Diego, California.
Late breaking data examines 10-year cost effectiveness of fremanezumab, while one oral presentation and 29 posters highlight FOCUS Phase IIIb study data in adult patients with migraine and documented inadequate response to 2-4 classes of prior preventive treatments, along with patient survey results and post hoc efficacy results following the 1-year Phase III HALO long-term study
The FDA has granted first approvals for the generic versions of Lyrica to Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, Dr. Reddy’s Laboratories, InvaGen Pharmaceuticals, MSN Laboratories Ltd., Rising Pharmaceuticals, Inc., Sciegen Pharmaceuticals Inc., and Teva Pharmaceuticals.
These results include reduction in monthly average migraine days; reduction in migraine related symptoms; and improvements in depression status; work productivity and activity impairment.
SEATTLE–(BUSINESS WIRE)–Just Biotherapeutics, Inc. (Just), an integrated design company focused on technologies for accelerating the development and manufacture of biotherapeutics,…
DUBLIN–(BUSINESS WIRE)–The “Real-World Data Capabilities: Benchmarking Pharma Companies (2019)” report has been added to ResearchAndMarkets.com’s offering. Are you fully and…
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today
announced the launch of a generic version of Tracleer®1
(bosentan) tablets, 62.5 mg and 125 mg, in the U.S.
Teva presents 17 posters and three oral presentations at EHF 2019 highlighting long-term and FOCUS Phase IIIb study data The…
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) todayannounced the launch of a generic version of Delzicol®1(mesalamine) delayed-release capsules, 400 mg, in the U.S.
Teva recalls 35 lots of bulk LosartanPotassium USP Tablets.